Biogen Inc. (BIIB)

202,46 +0,47 (+0,23 %) À la clôture : 04:00PM EDT

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
https://www.biogen.com

Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - General
Employés à temps plein: 7 570

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Christopher A. Viehbacher	President, CEO & Director	487,94k	S.O.	1961
Mr. Michael R. McDonnell CPA	Executive VP & CFO	2,12M	S.O.	1964
Ms. Nicole Murphy	Head of Pharmaceutical Operations & Technology	1,46M	S.O.	S.O.
Ms. Susan H. Alexander Esq.	Executive VP & Chief Legal Officer	2,2M	S.O.	1957
Dr. Ginger Gregory	Executive VP & Chief Human Resources Officer	1,59M	S.O.	1968
Ms. Robin C. Kramer	Senior VP & Chief Accounting Officer	S.O.	S.O.	1966
Mr. Charles E. Triano	Senior VP & Head of Investor Relations	S.O.	S.O.	S.O.
Ms. Natacha Gassenbach	Chief Communication Officer & Head of Corporate Affairs	S.O.	S.O.	S.O.
Mr. Adam Keeney Ph.D.	Executive VP & Head of Corporate Development	S.O.	S.O.	S.O.
Ms. Alisha A. Alaimo	President & Head of North America	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2022 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Biogen Inc. en date du 1 avril 2024 est 6. Les scores principaux sont Audit : 9; Société : 5; Droits des actionnaires : 2; Compensation : 9.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.